BRIEF-Amgen Canada - announces new study results of Repatha in statin-intolerant patients
April 4 (Reuters) - Amgen Canada
* New detailed data from phase 3 gauss-3 trial evaluating repatha in patients with high cholesterol who cannot tolerate statins
* Repatha shown to significantly reduce LDLC-C by about 55 percent after 24 weeks compared to ezetimibe Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.